- Investors & Partners
- Meet our team
- Copyright © 2023
- All rights reserved
PRECIRIX’ platform allows the design and development of novel
radiopharmaceuticals or targeted radioligand therapies, a
technology in which radionuclides are attached to ligands that
direct them to their specific target on the cancer cell. The
radioactive payload is delivered in a highly selective manner to the
tumor, limiting radiation to the rest of the body.
Our technology platform facilitates development of sdAbs for multiple targets, in combination with different isotopes and applicability in various settings.
On target in minutes after IV infusion anywhere in the body. Deep tumor penetration and prolonged tumor retention. Rapid renal clearance of unbound product.
Direct cell killing and bystander effects.
Our lead product candidate, CAM-H2, consists of an HER2-targeting single-domain antibody linked to iodine-131. This targeted radioligand therapy is being developed for the treatment of patients with metastatic HER2-positive cancer indications, such as breast and gastric adenocarcinoma.
In addition to the lead program, the company has two compounds in advanced preclinical stage, targeting fibroblast activation protein and folate receptor alpha.
PRECIRIX’ research program further focuses on the evaluation of different linkers, isotopes and new sdAbs.
|Pre-clinical||Phase Ⅰ||Phase Ⅰ/Ⅱ||Phase Ⅲ||Market|
|CAM-H2 HER2+ Metastatic Cancer|
|CAM-FAP FAP+ cancer|
|CAM-FR FRa+ cancer|
The company is conducting a Phase I/II study to evaluate CAM-H2 treatment in patients with advanced / metastatic HER2-positive breast and gastroesophageal cancer.
Research demonstrated the specific uptake of CAM-H2 in brain lesions of patients with brain metastases from HER2-positive breast carcinoma. Therefore, the phase I/II trail will evaluate the impact of CAM-H2 on brain metastases, which are frequently observed in metastatic breast cancer.
The trial includes a dose-escalation and dose-expansion phase and will report safety, tolerability and dosimetry, as well as objective response rates, progression-free survival, overall survival, and duration of responses.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.